TRH Financial LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 15.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 20,196 shares of the company’s stock after buying an additional 2,670 shares during the period. Johnson & Johnson accounts for approximately 2.0% of TRH Financial LLC’s holdings, making the stock its 11th biggest position. TRH Financial LLC’s holdings in Johnson & Johnson were worth $3,007,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Lake Point Wealth Management increased its stake in Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after buying an additional 169 shares in the last quarter. Islay Capital Management LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth $42,000. FAI Wealth Management boosted its holdings in shares of Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC boosted its holdings in shares of Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

Several research firms have commented on JNJ. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a report on Tuesday, July 7th. Citigroup increased their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Raymond James increased their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the company from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and a consensus target price of $164.93.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.

Shares of NYSE JNJ opened at $148.10 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market cap of $389.92 billion, a P/E ratio of 23.29, a PEG ratio of 3.36 and a beta of 0.68. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The firm has a 50-day simple moving average of $148.57 and a two-hundred day simple moving average of $146.59.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.12 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 8 EPS for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: What is the LIBOR?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.